These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
391 related articles for article (PubMed ID: 29413052)
1. Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases. Gauvain C; Vauléon E; Chouaid C; Le Rhun E; Jabot L; Scherpereel A; Vinas F; Cortot AB; Monnet I Lung Cancer; 2018 Feb; 116():62-66. PubMed ID: 29413052 [TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data. Dudnik E; Moskovitz M; Daher S; Shamai S; Hanovich E; Grubstein A; Shochat T; Wollner M; Bar J; Merimsky O; Zer A; Goldstein DA; Hammerman A; Cyjon A; Shechtman Y; Abu-Amna M; Flex D; Roisman LC; Peled N; Lung Cancer; 2018 Dec; 126():217-223. PubMed ID: 29254746 [TBL] [Abstract][Full Text] [Related]
3. Comparable outcomes of nivolumab in patients with advanced NSCLC presenting with or without brain metastases: a retrospective cohort study. Zhang G; Cheng R; Wang H; Zhang Y; Yan X; Li P; Zhang M; Zhang X; Yang J; Niu Y; Ma Z Cancer Immunol Immunother; 2020 Mar; 69(3):399-405. PubMed ID: 31907567 [TBL] [Abstract][Full Text] [Related]
4. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. Ricciuti B; Genova C; De Giglio A; Bassanelli M; Dal Bello MG; Metro G; Brambilla M; Baglivo S; Grossi F; Chiari R J Cancer Res Clin Oncol; 2019 Feb; 145(2):479-485. PubMed ID: 30506406 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of the efficacy and safety of nivolumab in the second- or later-line treatment of patients with locally advanced/metastatic non-small cell lung cancer in Türkiye: a retrospective multicenter non-interventional registry study. Karadurmus N; Kaplan MA; Sendur MAN; Urun Y; Demirci U; Karaca SB; Goktas Aydin S; Aykan MB; Bilici A; Sezer A; Yilmaz U; Abali H; Yumuk PF; Degirmencioglu S; Demirkazik A; Paydas S; Mirili C; Turna H; Kargi A; Ozdogan M; Guven DC; Ozguroglu M; Kilickap S Curr Med Res Opin; 2024 Jul; 40(7):1171-1178. PubMed ID: 38809230 [TBL] [Abstract][Full Text] [Related]
6. Three-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: Pooled analysis of ONO-4538-05 and ONO-4538-06 studies. Horinouchi H; Nishio M; Hida T; Nakagawa K; Sakai H; Nogami N; Atagi S; Takahashi T; Saka H; Takenoyama M; Katakami N; Tanaka H; Takeda K; Satouchi M; Isobe H; Maemondo M; Goto K; Hirashima T; Minato K; Sumiyoshi N; Tamura T Cancer Med; 2019 Sep; 8(11):5183-5193. PubMed ID: 31353840 [TBL] [Abstract][Full Text] [Related]
7. Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy. Gataa I; Mezquita L; Rossoni C; Auclin E; Kossai M; Aboubakar F; Le Moulec S; Massé J; Masson M; Radosevic-Robin N; Alemany P; Rouanne M; Bluthgen V; Hendriks L; Caramella C; Gazzah A; Planchard D; Pignon JP; Besse B; Adam J Eur J Cancer; 2021 Mar; 145():221-229. PubMed ID: 33516050 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study. Fujimoto D; Yoshioka H; Kataoka Y; Morimoto T; Kim YH; Tomii K; Ishida T; Hirabayashi M; Hara S; Ishitoko M; Fukuda Y; Hwang MH; Sakai N; Fukui M; Nakaji H; Morita M; Mio T; Yasuda T; Sugita T; Hirai T Lung Cancer; 2018 May; 119():14-20. PubMed ID: 29656747 [TBL] [Abstract][Full Text] [Related]
9. [Therapeutic effect of nivolumab on non-small-cell lung cancer patients with brain metastases: a retrospective study]. Zhang GW; Cheng RR; Wang HJ; Zhang Y; Li P; Yan XT; Zhang MN; Zhang XJ; Yang JP; Ma ZY Zhonghua Zhong Liu Za Zhi; 2020 Nov; 42(11):961-965. PubMed ID: 33256309 [No Abstract] [Full Text] [Related]
10. Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: A national data base analysis. Giaj Levra M; Cotté FE; Corre R; Calvet C; Gaudin AF; Penrod JR; Grumberg V; Jouaneton B; Jolivel R; Assié JB; Chouaïd C Lung Cancer; 2020 Feb; 140():99-106. PubMed ID: 31911324 [TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of immune checkpoint inhibitors: A retrospective study in Taiwan. Hsu JC; Lin JY; Hsu MY; Lin PC PLoS One; 2018; 13(8):e0202725. PubMed ID: 30142174 [TBL] [Abstract][Full Text] [Related]
12. Clinical Experience of Immunotherapy Treatment: Efficacy and Toxicity Analysis of the Compassionate Use Program of Nivolumab in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer. Krefting F; Basara N; Schütte W; Späth-Schwalbe E; Alt J; Thiel S; Kimmich M; Fischer JR; Kurz S; Griesinger F; Christoph DC Oncol Res Treat; 2019; 42(5):243-255. PubMed ID: 30995666 [TBL] [Abstract][Full Text] [Related]